Watchman Device for Left Atrial Appendage Closure in High-Risk AF Patients
The Watchman left atrial appendage occlusion device is indicated for patients with non-valvular atrial fibrillation, CHA₂DS₂-VASc score ≥2, and contraindications to long-term oral anticoagulation due to high bleeding risk (HAS-BLED ≥3). 1, 2
Device Indication and Patient Selection
The FDA-approved indication specifically includes patients with non-valvular AF who are at risk for stroke, suitable for short-term anticoagulation, but have a rationale for seeking a non-pharmacologic alternative to long-term oral anticoagulation. 1
Qualifying Criteria:
- CHA₂DS₂-VASc score ≥2 (or ≥1 in women when counting sex as a point) indicating elevated thromboembolic risk 3, 4
- HAS-BLED score ≥3 indicating high bleeding risk, which represents a contraindication to long-term anticoagulation 2
- Absolute contraindications to anticoagulation include: active major bleeding, severe uncontrolled hypertension (>180/120 mmHg), history of intracranial hemorrhage with high recurrence risk, end-stage liver disease with coagulopathy, severe thrombocytopenia (<50,000/μL), or hypersensitivity to all available anticoagulants 2
Important Context:
The pivotal PROTECT AF trial demonstrated non-inferiority of Watchman to warfarin for stroke prevention, but enrolled only warfarin-eligible patients. 5 The ASAP study specifically evaluated patients deemed ineligible for warfarin (mean CHADS₂ 2.8, CHA₂DS₂-VASc 4.4), with 93% having history of hemorrhagic/bleeding tendencies, and demonstrated an ischemic stroke rate of 1.7% per year compared to an expected 7.3% per year based on risk scores. 5
Post-Implant Antithrombotic Regimen
The recommended post-implant antithrombotic strategy differs based on the patient's ability to tolerate any anticoagulation:
Standard Post-Implant Protocol (for patients who can tolerate short-term anticoagulation):
- Warfarin (INR 2.0-3.0) for 45 days post-implantation 6, 7
- Transition to dual antiplatelet therapy (aspirin plus clopidogrel) after 45-day transesophageal echocardiography (TEE) confirms adequate LAA closure without device-related thrombus 6, 7
- Continue dual antiplatelet therapy until 6 months post-implant 5
- Transition to aspirin monotherapy indefinitely after 6 months 5
Alternative Protocol for Patients Unable to Tolerate Warfarin:
The ASAP study protocol used dual antiplatelet therapy (aspirin 325 mg plus clopidogrel 75 mg) immediately post-procedure without warfarin transition, demonstrating safety and efficacy in patients with absolute contraindications to anticoagulation. 5
- Aspirin 325 mg plus clopidogrel 75 mg daily for 6 months post-implant 5
- Transition to aspirin 325 mg monotherapy indefinitely after 6 months 5
NOAC Alternative:
Direct oral anticoagulants (DOACs) may be used as an alternative to warfarin for the initial 45-day period, with 55% of patients in contemporary registries receiving NOACs post-procedure. 8
Procedural Safety and Outcomes
Device implantation success rates exceed 98% in experienced centers, with serious adverse event rates of 1.4-8.7% at 30 days. 6, 8, 7
Key Safety Metrics:
- Device-related thrombus formation occurs in approximately 4% of patients at 45-day follow-up 6
- Pericardial effusion requiring intervention occurs in <2% of cases 8, 7
- Device embolization is rare (<1%) with proper sizing and technique 6, 7
- Peridevice leak >5mm occurs in approximately 25% initially but typically resolves by 45-day follow-up 7
Critical Follow-Up Requirements
Mandatory TEE at 45 days post-implant to assess:
- Device position and stability 6, 7
- Presence of device-related thrombus 6, 7
- Peridevice leak assessment 7
- Determination of whether anticoagulation can be safely discontinued 6
Additional follow-up TEE at 6 months and 12 months to monitor for late complications and confirm continued adequate LAA closure. 6
Common Pitfalls to Avoid
- Do not implant Watchman in patients with valvular AF (moderate-to-severe mitral stenosis or mechanical valves), as these patients require lifelong anticoagulation regardless 3, 9
- Do not discontinue anticoagulation before 45-day TEE confirmation of adequate device positioning without thrombus 6, 7
- Do not use aspirin monotherapy as stroke prevention in AF patients—it is ineffective and still carries bleeding risk 4, 10
- Do not assume all patients with HAS-BLED ≥3 are contraindicated for anticoagulation—address modifiable bleeding risk factors first (hypertension control, alcohol cessation, medication adjustments) 2, 10
- Do not proceed with Watchman implantation without confirming patient can tolerate at least short-term antithrombotic therapy (either warfarin/NOAC for 45 days or dual antiplatelet therapy for 6 months) 5
Institutional Requirements
Watchman implantation should only be performed at centers with:
- Multidisciplinary team including interventional cardiology, electrophysiology, and cardiac imaging expertise 1
- Immediate cardiac surgery backup capability for emergency complications 1
- Operators with specific training and credentialing in LAA closure techniques 1
- TEE capability for procedural guidance and follow-up assessment 1, 7